Sutro Biopharma Appoints Jane Chung as Chief Commercial Officer
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced the appointment of Jane Chung to the newly-created position of Chief Commercial Officer, effective August 9, 2021.
Ms. Chung will provide patient, provider, thought leader, and reimbursement insights as Sutro’s clinical programs advance. Ms. Chung will envision and lead an emerging commercial focus within Sutro, including engagement of the various oncology communities and stakeholders as well as planning for sales, marketing, and market access functions for the company. Ms. Chung has more than 20 years of pharmaceutical and biotechnology experience, most recently having served as President of AstraZeneca Canada, as well as previous roles at Onyx Pharmaceuticals and Genentech and is a registered pharmacist.
“The addition of Jane to Sutro’s leadership team is crucial as we prepare for key milestones in our programs, including the continued development of STRO-002, our FolRα targeting ADC and STRO-001, our CD-74 targeting ADC” said Bill Newell, Chief Executive Officer of Sutro. “Jane has a proven track record of setting commercial strategies and in shepherding products from clinical to commercial stage. We look forward to working with Jane as Sutro continues to deliver critical therapies to patients with cancer.”
Jane Chung added, “I am incredibly excited to be joining Sutro to support the strategic planning of commercializing the pipeline and advancing the science. Sutro’s unique technology platform designed to develop next-generation cancer treatments with speed and scale is highly differentiated, and when combined with its innovative science and entrepreneurial culture, can potentially transform standard of care for cancer patients and improve their lives.”
As President of AstraZeneca Canada, Ms. Chung led all commercial functions within a broad pipeline of Oncology, Respiratory, Immunology, Cardiology, Renal and Metabolism therapeutic areas. Prior, she was Vice President and Head of AstraZeneca’s U.S. Immuno-Oncology franchise, and earlier she served as Senior Commercial Business Director and led the build-out of an expanded U.S. Oncology team. Before joining AstraZeneca in 2015, Ms. Chung was Oncology Region Sales Director and Hematology Director at Onyx Pharmaceuticals in San Francisco. From 2003 to 2013, Ms. Chung held diverse leadership roles at Genentech in Commercial Operations, Marketing and Sales.
Ms. Chung received her B.A. from Columbia University, New York, and pharmacy degree from St. John’s University, New York.
People In This Post
Companies In This Post
- Coeptis Therapeutics Secures Exclusive Rights to Negotiate the Acquisition of Transformational Cell Therapy Platform Read more
- SamaCare Partners with AmerisourceBergen to Offer Prior Authorization Platform to Specialty Practices Read more
- Lucy Therapeutics Appoints Neuroscience Drug Discovery and Development Expert Christopher J. Winrow, Ph.D., as Chief Scientific Officer Read more
- BGI Genomics Partners with Zentya to Launch Fecal DNA Test for Colorectal Cancer in Slovakia Read more
- PharmaVentures Establishes an Office in Seoul to Enhance Access for South Korean Biotechs Read more